SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K reports on the results of the 2013 Annual Meeting of Stockholders held on October 18, 2013. The registrant is Hemispherx Biopharma, Inc., a Delaware corporation. A quorum of 33.3% was present at the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three primary matters:
- Election of Directors: All five nominees were elected. Peter W. Rodino, III received the highest support (19,633,622 votes for), while Iraj E. Kiani received the lowest (16,787,204 votes for). Significant broker non-votes (69,564,045) were recorded for all director elections.
- Ratification of Independent Accountants: Stockholders approved the appointment of McGladrey LLP with 87,101,794 votes for, 2,538,111 against, and 1,142,057 abstentions.
- Executive Compensation Advisory Vote: The non-binding resolution on executive compensation elements was rejected. Votes were 9,289,452 for, 11,418,922 against, and 509,143 abstentions. Broker non-votes totaled 69,564,045.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. It references a press release dated October 18, 2013 (Exhibit 99.1) for additional information.
Key Facts for Investor Verification
- Verify the company's response to the failed advisory vote on executive compensation.
- Review the referenced press release (Exhibit 99.1) for details on the meeting and future strategic plans.
- Confirm the impact of the high volume of broker non-votes on future governance decisions.